Smith & Nephew launches uterine fibroid device; DioGenix raises cash to study MS diagnostic;

 @FierceMedDev: Quidel wins 510(k) for C. difficile molecular Dx. More | Follow @FierceMedDev

@MarkHFierce: More Dx funding--this time for Ortho Kinematics, a spine imaging Dx company--$2M Series B. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic posts more good renal denervation data, but it faces mounting competition from $BSX, $STJ. Story | Follow @DamianFierce

> A South Dakota hospital became only the fifth health system in the country to start using robots to assist with stent placement. Corindus Vascular Robotics developed this latest system. Story

> Smith & Nephew ($SNN) has launched the Truclear Ultra Reciprocating Morcellator, designed for the removal of uterine fibroids, which affect about 80% of women, the company says. News

> 2012 Fierce 15 winner T2 Biosystems snagged a patent for its T2MR platform, used in its T2Candida diagnostic that tests for 5 species of a leading hospital-acquired infection. More

> Many women who receive inconclusive BRCA tests choose risky and often unneeded ovarian cancer diagnostics, according to a new survey. Story

> Molecular diagnostics outfit DioGenix has raised $1.5 million to support a prospective, multi-site clinical trial to validate MSPrecise, a test for multiple sclerosis. Release

> Tyrx, a 2012 Fierce 15 medical device company, is reporting positive clinical trial results for its new AIGISRx antibacterial envelope, which is designed to reduce infection with pacemakers and implantable defibrillators. Item

> Clear Guide Medical, a Johns Hopkins spinoff, is developing a device used for minimally invasive ultrasound surgical device with an eye toward a 2014 commercial launch. Story

Biotech News

 @FierceBiotech: Celgene wraps $500M deal to partner with Sutro on next-gen ADCs. Article | Follow @FierceBiotech

@JohnCFierce: Hey, Actelion is (kind of) on a roll, with positive psoriasis data on PhII drug. Handily beats placebo. Article | Follow @JohnCFierce

@RyanMFierce: Interesting how Merck is using GE's experimental imaging agent in Alzheimer's trial for MK-8931. Does this add risk? Report | Follow @RyanMFierce

> Vanda shares soar on positive PhIII data. Item

> Troubled drug developer Enzon looks for buyer as Icahn asks for chat. News

> Langer biotech adds $16M in venture cash to back next-gen cancer drugs. Story

Pharma News

@FiercePharma: A blow to Roche's Avastin hopes as NICE rejects it for ovarian cancer. Article | Follow @FiercePharma

> Mylan chief jets to pop singer son's concerts on company aircraft. Story

> Amgen on verge of guilty plea in $780M settlement. News

Pharma Manufacturing News

> ICIG adds Tessenderlo plants to its portfolio. Report

> Teva puts brakes on $300M Philly warehouse. News

> FDA's counterfeit drug probe sweeps up cancer doc. Article

Biotech Research News

> Acetylon's HDAC drug fights sickle cell disease, beta thalassemia in blood cell studies. Item

> Lifting the mood: Antidepressant could double as diabetes drug. Report

> Engineered viruses rebuild heartbeat. Article

> Rejected diabetes drug wakes up cell memories in Alzheimer's. News

> Gene therapy flips switch in sickle cell disease. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.